Oleocanthal may help prevent, treat Alzheimer’s
“The results can help identify effective preventive measures and lead to improved therapeutics in the fight against Alzheimer’s disease,” said co-leader Paul AS Breslin, PhD, a sensory psychologist at the Monell Center.
Known as ADDLs, these highly toxic proteins bind neuronal synapses in the brains of Alzheimer’s patients and is thought to directly alter the function of nerve cells, eventually leading to memory loss, cell death, and global disturbance of cerebral function. Synapses are specialized junctions that allow one nerve cell to send information to another.
“The union of ADDLs to synapses of nerve cells is thought to be a crucial first step in the onset of Alzheimer’s disease. Oleocanthal pers alters the structure of a way to discourage people from binding to synapses,” said William L . Klein, PhD, who co-led the research with Breslin. “Translational studies are needed to link these laboratory findings to clinical interventions. Klein is Professor of Neurobiology and Physiology and a member of the Cognitive Neurology and Alzheimer’s Disease Center at Northwestern University.
Klein and his colleagues identified ADDLs in 1998, resulting in a significant shift in thinking about the causes, development and treatment of Alzheimer’s disease. Also known as beta-amyloid oligomers, ADDLs are structurally different from the amyloid plaques that accumulate in the brains of Alzheimer’s patients.
Reporting on a series of in vitro studies, the team of researchers at Northwestern Monell and found that incubation with oleocanthal ADDLs changed the structure by increasing the size of the protein.
Knowing that oleocanthal pers size changed, the researchers investigated whether oleocanthal affected the ability of ADDLs to force the synapses of cultured hippocampal neurons. The hippocampus, a part of the brain intimately involved in learning and memory, is one of the first areas affected by Alzheimer’s disease.
Measurement pers oleocanthal binding and without, they found that small amounts of oleocanthal effectively reduced binding of ADDLs to synapses in the hippocampus. Further studies revealed that oleocanthal could protect synapses of structural damage caused by ADDLs.
An unexpected finding was that ADDLs oleocanthal stronger in the objectives of the antibodies. This action provides an opportunity for creating more effective immunotherapy treatments that use antibodies bind and ADDLs attack.
Breslin commented on the implications of the findings. “If the antibody treatment of Alzheimer’s disease is reinforced by oleocanthal, the collective struggle against the toxic and immunological effects of this compound may lead to a successful treatment for an incurable disease. Just say for certain clinical trials.
In earlier work in Monell, Breslin and colleagues used the sensory properties of extra virgin olive oil to identify oleocanthal based on the quality of oral irritation similar to ibuprofen. Oleocanthal and ibuprofen also have similar anti-inflammatory properties, and ibuprofen – such as extra virgin olive oils, presumably rich in oleocanthal – is associated with reduced risk of Alzheimer’s disease when used regularly.
Future studies to determine more precisely how changes in the structure oleocanthal pers can increase understanding of the pharmacological actions of plant compounds oleocanthal, ibuprofen and structurally related. Such views may lead to drug discoveries related to disease prevention and treatment.
The results are reported in the Oct. 15 issue of Toxicology and Applied Pharmacology.
Tags: addl, addls, alzheimer, binding, binding of addls, brains of alzheimer, breslin, cell, disease, extra virgin olive, findings, ibuprofen, nerve, nerve cell, oleocanthal, structure, studies, synapses, treatment, treatment of alzheimer